111 Capital Purchases Shares of 2,506 Natera, Inc. (NASDAQ:NTRA)

111 Capital acquired a new position in shares of Natera, Inc. (NASDAQ:NTRA - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 2,506 shares of the medical research company's stock, valued at approximately $397,000.

A number of other institutional investors and hedge funds also recently made changes to their positions in the stock. LRI Investments LLC bought a new position in Natera in the 4th quarter valued at about $29,000. Blue Trust Inc. lifted its position in Natera by 104.3% in the 4th quarter. Blue Trust Inc. now owns 190 shares of the medical research company's stock valued at $30,000 after acquiring an additional 97 shares in the last quarter. EverSource Wealth Advisors LLC lifted its position in Natera by 372.9% in the 4th quarter. EverSource Wealth Advisors LLC now owns 331 shares of the medical research company's stock valued at $52,000 after acquiring an additional 261 shares in the last quarter. Principal Securities Inc. lifted its position in Natera by 20.7% in the 4th quarter. Principal Securities Inc. now owns 344 shares of the medical research company's stock valued at $54,000 after acquiring an additional 59 shares in the last quarter. Finally, Steward Partners Investment Advisory LLC lifted its position in Natera by 1,328.0% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 357 shares of the medical research company's stock valued at $57,000 after acquiring an additional 332 shares in the last quarter. Institutional investors own 99.90% of the company's stock.

Insider Transactions at Natera

In related news, Director Gail Boxer Marcus sold 4,000 shares of Natera stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $147.69, for a total value of $590,760.00. Following the completion of the transaction, the director now directly owns 9,704 shares in the company, valued at approximately $1,433,183.76. The trade was a 29.19% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider John Fesko sold 343 shares of Natera stock in a transaction that occurred on Monday, April 21st. The shares were sold at an average price of $145.55, for a total transaction of $49,923.65. Following the completion of the transaction, the insider now owns 156,946 shares of the company's stock, valued at $22,843,490.30. This represents a 0.22% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 152,436 shares of company stock worth $22,019,079 in the last quarter. Insiders own 7.60% of the company's stock.

Wall Street Analyst Weigh In

NTRA has been the topic of several recent research reports. Barclays raised their price target on shares of Natera from $160.00 to $190.00 and gave the company an "overweight" rating in a research report on Friday, May 9th. Royal Bank of Canada initiated coverage on shares of Natera in a research note on Thursday, March 13th. They issued an "outperform" rating and a $251.00 price objective for the company. Robert W. Baird increased their price objective on shares of Natera from $183.00 to $188.00 and gave the company an "outperform" rating in a research note on Friday, February 28th. UBS Group increased their price objective on shares of Natera from $211.00 to $218.00 and gave the company a "buy" rating in a research note on Friday, May 9th. Finally, Wall Street Zen lowered shares of Natera from a "hold" rating to a "sell" rating in a research note on Saturday, May 17th. One research analyst has rated the stock with a sell rating and sixteen have issued a buy rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $182.12.

Natera Stock Performance

Shares of NTRA stock traded down $0.54 during trading hours on Tuesday, hitting $160.15. 930,705 shares of the company were exchanged, compared to its average volume of 1,404,449. The firm has a fifty day simple moving average of $150.36 and a 200 day simple moving average of $158.52. The company has a current ratio of 4.39, a quick ratio of 4.23 and a debt-to-equity ratio of 0.33. Natera, Inc. has a 52-week low of $92.14 and a 52-week high of $183.00. The stock has a market capitalization of $21.87 billion, a price-to-earnings ratio of -90.99 and a beta of 1.79.

Natera (NASDAQ:NTRA - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The medical research company reported ($0.50) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.59) by $0.09. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. The company had revenue of $501.83 million during the quarter, compared to analyst estimates of $446.68 million. During the same quarter last year, the business posted ($0.56) EPS. Natera's quarterly revenue was up 36.5% compared to the same quarter last year. Research analysts predict that Natera, Inc. will post -1.49 earnings per share for the current fiscal year.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.